Nombre del producto:3-Hydrazino-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazine

IUPAC Name:5-hydrazinyl-3,4-diazatricyclo[9.4.0.0²,⁷]pentadeca-1(15),2,4,6,11,13-hexaene

CAS:802598-74-9
Fórmula molecular:C13H14N4
Pureza:95%+
Número de catálogo:CM337866
Peso molecular:226.28

Unidad de embalaje Stock disponible Precio($) Cantidad
CM337866-100mg in stock ʼnưǵ
CM337866-250mg in stock NJƞȎ
CM337866-1g 1-2 Weeks ʼnʼnNJǵ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :802598-74-9
Fórmula molecular:C13H14N4
Punto de fusión:-
Código de sonrisas:NNC1=NN=C2C(CCCC3=CC=CC=C32)=C1
Densidad:
Número de catálogo:CM337866
Peso molecular:226.28
Punto de ebullición:
Nº Mdl:
Almacenamiento:2-8ºC

Column Infos

Bemcentinib
Bemcentinib is a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. Extensive studies confirm the ability to combine bemcentinib with immune checkpoint inhibitors, chemotherapies and targeted therapies with the goal of improving a patient’s immune response and delaying the development of chemoresistance. Bemcentinib is currently being investigated in combination with immune checkpoint inhibition and chemotherapy in first line NSCLC patients harboring mutations in the STK11 gene, a known prognostic factor of poor response to existing therapies.

Related Products